Department of Child Neurology, Medical University, Lublin, Poland.
Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin, Poland.
Seizure. 2019 Jul;69:265-272. doi: 10.1016/j.seizure.2019.05.006. Epub 2019 May 9.
There is growing evidence to support the role of the kynurenine pathway in the anticonvulsant efficacy of ketogenic diets (KDs) in refractory epilepsy. The aim of the present study was to measure blood levels of tryptophan (TRP) and its kynurenine derivatives and correlate them with seizure reduction after starting the KD in children with refractory epilepsy.
Sixteen children (9 F/7 M; 7.1 ± 5.1 years) with refractory epilepsy were treated with the KDs. Clinical efficacy and metabolic ketosis were monitored throughout the study; blood levels of TRP, kynurenine (KYN), kynurenic acid (KYNA), and 3-OH-kynurenine (3-OH-KYN) were measured at 3, 6, and 12 months on the diet and compared to the pre-KD levels.
Out of 16 children, 14 attained a ≥50% reduction (responders) in seizure frequency 3 months after starting the KD. In the 14 responders, TRP levels decreased numerically (18-25%) but not significantly (P = 0.077) compared to the pre-KD control values. KYN levels decreased significantly (30-57%; P = 0.001) compared to the pre-KD control levels while KYNA levels significantly increased (38-96%; P < 0.001). KYNA/KYN ratios significantly increased (100-323%; P = 0.003) while 3-OH-KYN levels (P = 0.680) and KYN/TRP ratios (P = 0.385) remained unchanged. Higher concentrations of KYNA and lower concentrations of KYN (P < 0.05) were found in patients who attained a higher reduction in seizure frequencies on the KD.
We report a pattern of changes in the blood level of kynurenines in patients with refractory epilepsy who started the KD. The results of this study further support the role of specific kynurenines (e.g. KYNA) in the efficacy of the KD in refractory epilepsy.
越来越多的证据支持犬尿氨酸途径在生酮饮食(KD)治疗难治性癫痫中的抗惊厥作用。本研究旨在测量难治性癫痫儿童开始 KD 后血液中色氨酸(TRP)及其犬尿氨酸衍生物的水平,并将其与发作减少相关联。
16 名(9 名女性/7 名男性;7.1±5.1 岁)难治性癫痫患儿接受 KD 治疗。在整个研究过程中监测临床疗效和代谢酮症;在开始 KD 后的 3、6 和 12 个月测量血液中 TRP、犬尿氨酸(KYN)、犬尿氨酸酸(KYNA)和 3-羟基犬尿氨酸(3-OH-KYN)的水平,并与 KD 前的水平进行比较。
16 名儿童中有 14 名在开始 KD 后 3 个月时癫痫发作频率降低≥50%(应答者)。在 14 名应答者中,TRP 水平下降(18-25%)但无统计学意义(P=0.077)与 KD 前的对照值相比。与 KD 前的对照水平相比,KYN 水平显著降低(30-57%;P=0.001),而 KYNA 水平显著升高(38-96%;P<0.001)。KYNA/KYN 比值显著增加(100-323%;P=0.003),而 3-OH-KYN 水平(P=0.680)和 KYN/TRP 比值(P=0.385)无变化。在 KD 降低癫痫发作频率更高的患者中,发现 KYNA 浓度更高,KYN 浓度更低(P<0.05)。
我们报告了难治性癫痫患者开始 KD 后血液中犬尿氨酸水平变化的模式。本研究结果进一步支持特定犬尿氨酸(如 KYNA)在 KD 治疗难治性癫痫中的疗效。